Semaglutide for Prediabetes: Evidence, Eligibility, Coverage

Semaglutide is not FDA approved for prediabetes. It is approved for type 2 diabetes, heart risk and kidney disease in type 2 diabetes. Some doctors prescribe it when one of those uses also applies. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.

Brands: Ozempic, Wegovy and Rybelsus
Best result (STEP 1): 14.9% weight loss

A quick look at Wegovy

How long it remains in the body

Its half-life is about 1 week: after 7 d, half is gone, and about 3% remains after five half-lives (35 d).

Weight loss in its main trial

In STEP 1 over 68 weeks, weight loss was 14.9% of body weight, compared with 2.4% on placebo.

Costs over time

The maker's price page lists monthly prices in US dollars, including the list price and self-pay offers.

Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.

Who qualifies?

Which people qualify for semaglutide
Who sets the rule	Who qualifies
Ozempic	It lowers blood sugar in adults with type 2 diabetes when used with diet and exercise.
Ozempic	In adults with heart disease and type 2 diabetes, the risk of a stroke, heart attack or heart-related death is lower.
Ozempic	For adults with chronic kidney disease and type 2 diabetes, this medicine reduces the chance of worsening kidney disease, kidney failure and heart-related death.
Wegovy	When adults have heart disease and obesity or overweight, stroke, heart attack and heart-related death become less likely with injection and tablets.
Wegovy	It helps adults and children 12 and older with obesity, and adults with overweight and a weight-related condition, lose weight and keep it off long term when used with diet and activity.
Wegovy	For adults, the injection treats MASH liver disease with scarring that is moderate to advanced and no cirrhosis.
Wegovy	In adults, the tablets are approved to support weight loss and reduce heart risk.
Rybelsus	It lowers blood sugar in adults with type 2 diabetes when used with diet and exercise.
Rybelsus	For high-risk adults with type 2 diabetes, it reduces the chance of a heart attack, a stroke or a heart-related death.
Medicare GLP-1 Bridge	BMI 35 or higher, no condition needed
Medicare GLP-1 Bridge	Uncontrolled blood pressure, heart failure or CKD 3a+, plus a BMI of 30 or above
Medicare GLP-1 Bridge	Prediabetes, PAD, or a previous heart attack or stroke, with a BMI of 27 or above
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	a diet and activity program lasting 6 months comes first

Sources: FDA label (DailyMed) 1 2 3, medicare.gov 1 2, aetna.com.

Trial results for prediabetes

These studies included participants beyond people with prediabetes. The adults enrolled had obesity or overweight and did not have diabetes.

Semaglutide trials: Prediabetes
Trial	Medicine	Who took part	Length	People	Main result	Comparison
STEP 1	Wegovy	Adults with obesity or overweight, without diabetes	68 weeks	1,961	14.9% weight loss	2.4% on placebo
OASIS 4	Wegovy	Adults with obesity or overweight, without diabetes	64 weeks	307	13.6% weight loss	2.4% on placebo

Source of the trial: STEP 1 (FDA label (DailyMed)).

What is different for prediabetes?

Semaglutide: label points for prediabetes
What changes	What the label says	Labels
Low Blood Sugar When You Also Use Insulin Secretagogues or Insulin	When used with insulin or a sulfonylurea, it makes low blood sugar more likely, so those doses may need lowering.	All of them
Taken with insulin or sulfonylureas	When combined with insulin or a sulfonylurea such as glipizide or glimepiride, this medicine increases the risk of low blood sugar.	All of them

These details come from the FDA labels: FDA label (DailyMed).

Label warnings: FDA label (DailyMed).

Coverage for prediabetes

Medicare Part D does not pay for a GLP-1 when it is used only for weight loss.

The Medicare GLP-1 Bridge lists Wegovy at $50 per month for people who meet its rules.

The standard is prior authorization when Medicaid covers weight-loss GLP-1s.

Sources: humana.com, CMS, KFF.

Alternatives for prediabetes

GLP-1 medicines and prediabetes
Medicine	For prediabetes	How it is taken	Trial result
Ozempic	Not a listed use	weekly injection	Not listed
Wegovy	Not a listed use	weekly injection or daily tablet	14.9% weight loss
Rybelsus	Not a listed use	daily tablet	Not listed
Mounjaro	Not a listed use	weekly injection	Not listed
Zepbound	Not a listed use	weekly injection	20.9% weight loss
Foundayo	Not a listed use	daily tablet	11.1% weight loss
Trulicity	Not a listed use	weekly injection	Not listed
Saxenda	Not a listed use	daily injection	7.4% weight loss
Victoza	Not a listed use	daily injection	Not listed
Byetta	Not a listed use	twice-daily injection	Not listed